JP2015096532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015096532A5 JP2015096532A5 JP2014255148A JP2014255148A JP2015096532A5 JP 2015096532 A5 JP2015096532 A5 JP 2015096532A5 JP 2014255148 A JP2014255148 A JP 2014255148A JP 2014255148 A JP2014255148 A JP 2014255148A JP 2015096532 A5 JP2015096532 A5 JP 2015096532A5
- Authority
- JP
- Japan
- Prior art keywords
- rasagiline
- parkinson
- pharmaceutically acceptable
- use according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 210
- 229960000245 rasagiline Drugs 0.000 claims description 209
- 208000018737 Parkinson disease Diseases 0.000 claims description 112
- 150000003839 salts Chemical class 0.000 claims description 103
- 208000024891 symptom Diseases 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 27
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical group CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 claims description 14
- 229960001956 rasagiline mesylate Drugs 0.000 claims description 14
- 230000000648 anti-parkinson Effects 0.000 claims description 7
- 239000000939 antiparkinson agent Substances 0.000 claims description 7
- 230000008717 functional decline Effects 0.000 claims description 7
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 4
- -1 Rebodoba Chemical compound 0.000 claims description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- 229960001081 benzatropine Drugs 0.000 claims description 4
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 4
- 229960002802 bromocriptine Drugs 0.000 claims description 4
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 4
- 229960004596 cabergoline Drugs 0.000 claims description 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 4
- 229960003337 entacapone Drugs 0.000 claims description 4
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 4
- 229960003089 pramipexole Drugs 0.000 claims description 4
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 4
- 229960001879 ropinirole Drugs 0.000 claims description 4
- 229960003179 rotigotine Drugs 0.000 claims description 4
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 4
- 229960003946 selegiline Drugs 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 4
- 229960004603 tolcapone Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 104
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13193608P | 2008-06-13 | 2008-06-13 | |
| US61/131,936 | 2008-06-13 | ||
| US18972408P | 2008-08-22 | 2008-08-22 | |
| US61/189,724 | 2008-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Division JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234976A Division JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015096532A JP2015096532A (ja) | 2015-05-21 |
| JP2015096532A5 true JP2015096532A5 (enExample) | 2015-07-02 |
Family
ID=41415378
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Pending JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
| JP2014255148A Pending JP2015096532A (ja) | 2008-06-13 | 2014-12-17 | パーキンソン病緩和のためのラサギリン |
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513503A Pending JP2011522892A (ja) | 2008-06-13 | 2009-06-12 | パーキンソン病緩和のためのラサギリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234976A Withdrawn JP2017081938A (ja) | 2008-06-13 | 2016-12-02 | パーキンソン病緩和のためのラサギリン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090312436A1 (enExample) |
| EP (2) | EP2296462A4 (enExample) |
| JP (3) | JP2011522892A (enExample) |
| CN (2) | CN103893160A (enExample) |
| AU (2) | AU2009258151A1 (enExample) |
| BR (1) | BRPI0909894A2 (enExample) |
| CA (1) | CA2727022A1 (enExample) |
| EA (1) | EA201170018A1 (enExample) |
| IL (1) | IL209131A0 (enExample) |
| MX (1) | MX2010013766A (enExample) |
| NZ (1) | NZ589445A (enExample) |
| WO (1) | WO2009151625A1 (enExample) |
| ZA (1) | ZA201008484B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060018957A1 (en) * | 2004-07-26 | 2006-01-26 | Lerner E I | Pharmaceutical dosage forms including rasagiline |
| ES2371883T3 (es) * | 2004-11-24 | 2012-01-11 | Teva Pharmaceutical Industries Ltd. | Composiciones de rasagilina de disgregación oral. |
| US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| AU2007235517B2 (en) | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EA201070842A1 (ru) * | 2008-01-11 | 2011-04-29 | Тева Фармасьютикал Индастриз, Лтд. | Препаративные формы разагилина, их получение и применение |
| AU2009258120B2 (en) * | 2008-06-10 | 2014-11-27 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| NZ589547A (en) | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| PT2451771E (pt) | 2009-07-09 | 2014-09-19 | Ratiopharm Gmbh | Sais de rasagilina e suas preparações farmacêuticas |
| WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
| RU2587330C2 (ru) * | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| WO2012015946A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| CN103188933A (zh) * | 2010-10-26 | 2013-07-03 | 泰华制药工业有限公司 | 富集氘的雷沙吉兰 |
| CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
| CA2851433A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
| BR112014008555A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-formil-propargil-aminoindano |
| US20130089611A1 (en) * | 2011-10-10 | 2013-04-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline citramide |
| AR092168A1 (es) | 2012-08-17 | 2015-03-25 | Teva Pharma | Formulaciones parenterales de rasagilina |
| CA2943841A1 (en) * | 2014-04-01 | 2015-10-08 | Teva Pharmaceutical Industries Ltd. | Determination of single nucleotide polymorphisms useful to predict response for rasagiline |
| EP3432931A1 (en) * | 2016-03-26 | 2019-01-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositons for n-propargylamine derivative |
| EP3606541A1 (en) * | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| CA3127590A1 (en) * | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
| GB202109826D0 (en) * | 2021-07-07 | 2021-08-18 | Bial Portela & Ca Sa | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| CA2275425C (en) * | 1996-12-18 | 2009-08-04 | Michael Chorev | Aminoindan derivatives |
| AU2002319615A1 (en) * | 2001-07-20 | 2003-03-03 | Mount Sinai School Of Medicine Of New York University | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
| CA2471760A1 (en) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Preventives/remedies for urinary disturbance |
| SI1567152T1 (sl) * | 2002-11-15 | 2013-10-30 | Teva Pharmaceutical Industries Ltd. | Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20060018957A1 (en) * | 2004-07-26 | 2006-01-26 | Lerner E I | Pharmaceutical dosage forms including rasagiline |
| ES2371883T3 (es) * | 2004-11-24 | 2012-01-11 | Teva Pharmaceutical Industries Ltd. | Composiciones de rasagilina de disgregación oral. |
| US7815942B2 (en) * | 2005-02-23 | 2010-10-19 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| US7491847B2 (en) * | 2005-11-17 | 2009-02-17 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| AU2007235517B2 (en) * | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| UA97382C2 (ru) * | 2006-12-14 | 2012-02-10 | Тева Фармасьютікл Індастріз, Лтд. | Таннат разагилина |
| AU2007334428B2 (en) * | 2006-12-14 | 2014-05-29 | Teva Pharmaceutical Industries, Ltd. | Crystalline solid rasagiline base |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032202A1 (en) * | 2007-08-29 | 2009-03-12 | Nuon Therapeutics, Inc. | Treatment of brain disorders |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| EA201070842A1 (ru) * | 2008-01-11 | 2011-04-29 | Тева Фармасьютикал Индастриз, Лтд. | Препаративные формы разагилина, их получение и применение |
| AU2009258120B2 (en) * | 2008-06-10 | 2014-11-27 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| JP2013507352A (ja) * | 2009-10-09 | 2013-03-04 | テバ ファーマシューティカル インダストリーズ リミティド | 進行性核上性麻痺の治療のためのラサギリンの使用 |
| WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
-
2009
- 2009-06-12 EP EP09762921A patent/EP2296462A4/en not_active Withdrawn
- 2009-06-12 MX MX2010013766A patent/MX2010013766A/es not_active Application Discontinuation
- 2009-06-12 JP JP2011513503A patent/JP2011522892A/ja active Pending
- 2009-06-12 WO PCT/US2009/003528 patent/WO2009151625A1/en not_active Ceased
- 2009-06-12 AU AU2009258151A patent/AU2009258151A1/en not_active Abandoned
- 2009-06-12 NZ NZ589445A patent/NZ589445A/xx unknown
- 2009-06-12 EP EP20130176166 patent/EP2666356A1/en not_active Withdrawn
- 2009-06-12 US US12/456,166 patent/US20090312436A1/en not_active Abandoned
- 2009-06-12 CN CN201310714021.5A patent/CN103893160A/zh active Pending
- 2009-06-12 CN CN2009801230031A patent/CN102065687A/zh active Pending
- 2009-06-12 EA EA201170018A patent/EA201170018A1/ru unknown
- 2009-06-12 CA CA2727022A patent/CA2727022A1/en not_active Abandoned
- 2009-06-12 BR BRPI0909894-1A patent/BRPI0909894A2/pt not_active IP Right Cessation
-
2010
- 2010-11-04 IL IL209131A patent/IL209131A0/en unknown
- 2010-11-25 ZA ZA2010/08484A patent/ZA201008484B/en unknown
-
2013
- 2013-11-27 US US14/092,526 patent/US20140243418A1/en not_active Abandoned
-
2014
- 2014-12-17 JP JP2014255148A patent/JP2015096532A/ja active Pending
-
2016
- 2016-11-15 AU AU2016259315A patent/AU2016259315A1/en not_active Abandoned
- 2016-12-02 JP JP2016234976A patent/JP2017081938A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oertel et al. | Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe | |
| JP2020528075A5 (enExample) | ||
| JP2019511488A5 (enExample) | ||
| JP2014505688A5 (enExample) | ||
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| EP3684411A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| JP2015505564A5 (enExample) | ||
| JP2017081938A (ja) | パーキンソン病緩和のためのラサギリン | |
| JP2017510607A5 (enExample) | ||
| WO2016083875A1 (en) | Medicaments for slowing parkinson's disease | |
| JP2016510343A5 (enExample) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| Roth et al. | The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study | |
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| JP2016505050A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2018505901A5 (enExample) | ||
| RU2325146C1 (ru) | Способ реабилитации больных рассеянным склерозом с нарушениями двигательных функций | |
| JP2017511307A5 (enExample) | ||
| Serafini et al. | The use of rotigotine in the treatment of restless legs syndrome | |
| JP2018500375A5 (enExample) | ||
| Godse et al. | “Busting” urticaria with a “burst” of steroids |